Best Practice & Research Clinical Endocrinology & Metabolism
Volume 17, Issue 1 , Pages 1-16 , March 2003

Medical choices available for management of menopause

  • Elizabeth Farrell, MBBS, FRANZCOG, FRCOG (Head of Unit)

      Affiliations

    • Corresponding Author InformationAddress for correspondence: 372, Albert Street, East Melbourne 3002, Australia. Tel.: +61-3-9419-4877; Fax: +61-3-9415-1709.

References 

  1. Writing Group for the Women's Health Initiative Investigators . Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Journal of the American Medical Association. 2002;228:321–333
  2. Bachmann GA. Vasomotor flushes in menopausal women. American Journal of Obstetrics and Gynecology. 1999;180:S312–S316
  3. Ho SC, Chan SG, Yip YB, et al.  Menopausal symptoms and symptom clustering in Chinese women. Maturitas. 1999;33:219–227
  4. Dennerstein L, Dudley EC, Hooper JL, et al.  A prospective population-based study of menopausal symptoms. Obstetrics and Gynecology. 2000;96:351–358
  5. Samsoie G. The menopause revisited. International Journal of Gynecology and Obstetrics. 1995;51:1–13
  6. Greene JG. Measuring the symptom dimension of quality of life: general and menopause-specific scales and their subscale structure. In:  Schneider HP editors. Hormone Replacement Therapy and Quality of Life. London: The Parthenon Publishing Group; 2002;p. 35–43
  7. A National GP Education Program. A National GP Education Program. Melbourne: The Jean Hailes Foundation; 2002;
  8. Whitehead M. The need for continuing education of the prescriber. Climacteric. 2000;3:S28–S32
  9. Ruggiero RJ. Patient communication and counselling on contraception and hormone replacement therapy. American Journal of Management and Care. 2001;7:S580–S585
  10. Cox KL, Burke V, Morton AR, et al.  Long-term effects of exercise on blood pressure and lipids in healthy women aged 40–65 years: the sedentary women exercise adherence trial (SWEAT). Journal of Hypertension. 2001;19:1733–1743
  11. Guthrie JR, Dudley EC, Hopper JL, Dennerstein L. Changes in physical activity and health outcomes in a population-based cohort of mid-life Australian-born women. Australia and New Zealand Journal of Public Health. 1997;21:1–6
  12. Rockhill B, Willett WC, Manson JE, et al.  Physical activity and mortality: a prospective study among women. American Journal of Public Health. 2001;91:578–583
  13. Slaven L, Lee C. Mood and symptom reporting among middle-aged women: the relationship between menopausal status, hormone replacement therapy, and exercise participation. Health and Psychology. 1997;16:203–208
  14. Ivarsson T, Spetz AC, Hammar M. Physical exercise and vasomotor symptoms in postmenopausal women. Maturitas. 1998;29:139–146
  15. Guthrie JR, Smith AM, Dennerstein L, Morse C. Physical activity and the menopause experience: a cross-sectional study. Maturitas. 1995;20:71–80
  16. Nelson ME, Fiatarone MA, Morganti CM, et al.  Effects of high intensity strength training on multiple risk factors for osteoporotic fractures: a randomised controlled trial. Journal of the American Medical Association. 1994;272:1909–1914
  17. Wark JD. Osteoporotic fractures: background and prevention strategies. Maturitas. 1996;23:193–207
  18. Hatori M, Hasegawa A, Adachi H, et al.  The effects of walking at the anaerobic threshold level on vertebral bone loss in postmenopausal women. Calcified Tissue International. 1993;52:411–414
  19. Bissiger M. Exercise guidelines for women with osteoporosis. Menopause Management. 2000;9:8–19
  20. Kohort WM, Ehsani AA, Birge SJ. HRT preserves increases in bone mineral density and reductions in body fat after a supervised exercise program. Journal of Applied Physiology. 1998;84:1506–1512
  21. Murkies AM, Wilcox G, Davis SR. Phytoestrogens. Journal of Clinical Endocrinology and Metabolism. 1999;83:297–303
  22. The role of calcium in peri- and postmenopausal women: a consensus opinion of the North American Menopause Society. Menopause. 2001;8:84–95
  23. McKinlay SM, Bifani NL, McKinlay JB. Smoking and age at menopause in women. Annals of Internal Medicine. 1985;122:350–356
  24. Singletary KW, Gapstur SM. Alcohol and breast cancer: review of the epidemiologic and experimental evidence of potential mechanisms. Journal of the American Medical Association. 2001;286:2143–2151
  25. Hulley S, Grady D, Bush T, et al.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Journal of the American Medical Association. 1998;280:605–613
  26. MacLennan A, Lester S, Moore V. Oral estrogen replacement therapy versus placebo for hot flushes: a systematic review. Climacteric. 2001;4:58–74
  27. Writing Group for the PEPI Trial . Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. Journal of the American Medical Association. 2001;285:2891–2897
  28. MacLennan AH, Wilson DH, Taylor AW. The prevalence and cost of alternative medicine in Australia. Lancet. 1996;347:569–573
  29. Lacey JV, Mink PJ, Lubin JH, et al.  Menopausal hormone replacement therapy and the risk of ovarian cancer. Journal of the American Medical Association. 2002;288:334–341
  30. Adams C, Cannell R. Women's beliefs about natural hormones and natural replacement therapy. Menopause. 2001;8:433–440
  31. Siahpush M. Postmodern values, dissatisfaction with conventional medicine and popularity of alternative medicines. Journal of Sociology. 1998;34:59–70
  32. Elkind-Hirsh K. Effect of dietary phytoestrogens on hot flushes: can soy-based proteins substitute for traditional estrogen replacement therapy?. Menopause. 2001;8:154–156
  33. Baber RJ, Templeman C, Morton T, et al.  Randomized placebo-controlled trial of an isoflavone supplement and menopausal symptoms in women. Climacteric. 1999;2:85–92
  34. Han KK, Soares JM, Haider MA, et al.  Benefits of soy isoflavone therapeutic regimen on menopausal symptoms. Obstetrics and Gynecology. 2002;99:389–394
  35. Davis SR, Briganti EM, Chen RQ, et al.  The effects of Chinese traditional medicinal herbs on postmenopausal vasomotor symptoms of Australian women—a randomised controlled trial. Medical Journal of Australia. 2001;174:68–71
  36. Amato P, Christophe S, Mellon P. Estrogenic activity of herbs commonly used as remedies for menopausal symptoms. Menopause. 2002;9:145–150
  37. Coope J. Hormonal and non-hormonal interventions for menopausal symptoms. Maturitas. 1996;23:159–168
  38. Greendale GA, Reboussin BA, Hogan P, et al.  Symptom relief and side effects of postmenopausal hormones: results from the postmenopausal estrogen/progestin interventions trial. Obstetrics and Gynecology. 1998;92:982–988
  39. Lobo RA, Whitehead MI. Is low-dose hormone replacement therapy for postmenopausal women efficacious and desirable?. Climacteric. 2001;4:110–119
  40. Cardozo L, Bachmann G, McClish D, et al.  Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the hormones and urogenital therapy committee. Obstetrics and Gynecology. 1998;92:722–727
  41. Vooijs GP, Geurts TB. Review of endometrial safety during intravaginal treatment with estriol. European Journal of Obstetrics and Gynecologn. 1995;62:101–106
  42. Ayton RA, Darling GM, Murkies AM, et al.  A comparative study of safety and efficacy of continuous low dose oestradiol released from a vaginal ring compared with conjugated equine oestrogen vaginal cream in the treatment of postmenopausal urogenital atrophy. British Journal of Obstetrics and Gynaecology. 1996;103:351–358
  43. Eriksen BC. A randomised, open, parallel-group study on the preventative effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. American Journal of Obstetrics and Gynecology. 1999;180:1072–1079
  44. Dennerstein L, Smith AM, Morse C. Psychological well-being, midlife and the menopause. Maturitas. 1994;20:1–11
  45. Mulnard RA, Cotman CW, Kawas C, et al.  Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease. Journal of the American Medical Association. 2000;283:1007–1015
  46. Sarrel PM, Dobay B, Wiita B. Estrogen and estrogen-androgen replacement in postmenopausal women dissatisfied with estrogen-only therapy: sexual behaviour and neuroendocrine responses. Journal of Reproductive Medicine. 1998;43:847–856
  47. Hodson J, Thompson J, Al-Azzawi F. Headache at menopause and in hormone replacement users. Climacteric. 2000;3:119–124
  48. Grodstein F, Colditz GA, Stampfer MJ. Postmenopausal hormone use and tooth loss: a prospective study. Journal of the American Dental Association. 1996;127:370–377
  49. Grady D, Gebretsadik T, Kerlikowske K, et al.  Hormone replacement therapy and endometrial cancer: a meta-analysis. Obstetrics and Gynecology. 1995;85:304–313
  50. Ross R, Paganini-Hill A, Wan P, Pike M. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. Journal of National Cancer Institute. 2000;92:328–332
  51. Montplaisir J, Lorrain MD, Denesle R, Petit D. Sleep in menopause: differential effects of two forms of hormone replacement therapy. Menopause. 2001;8:10–16
  52. Archer D. The effect of the duration of progestin use on the occurrence of endometrial cancer in postmenopausal women. Menopause. 2001;8:245–251
  53. Leonetti HB, Longo S, Anasti JN. Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. Obstetrics and Gynecology. 1999;94:225–228
  54. Wren BG, McFarland K, Edwards P, et al.  Effect of sequential transdermal progesterone cream on endometrium, bleeding pattern, and plasma and salivary progesterone levels in postmenopausal women. Climacteric. 2002;3:155–160
  55. Palacios S. Tibolone: what does tissue specific activity mean?. Maturitas. 2001;37:159–165
  56. Modelska K, Cummings S. Tibolone for postmenopausal women: systematic review of randomised trials. Journal of Clinical Endocrinology and Metabolism. 2002;87:16–23
  57. Davis SR. The effects of tibolone on mood and libido. Menopause. 2002;3:162–170
  58. Irvin JL, Domar AD, Clark C, et al.  The effects of relaxation response training on menopausal symptoms. Journal of Psychology in Obstetrics and Gynaecology. 1996;17:202–207
  59. Miller KL. Alternatives to estrogen for menopausal symptoms. Clinical Obstetrics and Gynecology. 1992;35:884–893
  60. Loprinzi CL, Kugler JW, Sloan JA, et al.  Venlaflaxine in management of hot flashes in survivors of breast cancer: a randomised control trial. Lancet. 2000;356:2059–2063
  61. Loprinzi CL, Sloan JA, Perez EA, et al.  Phase III evaluation of fluoxetine for treatment of hot flushes. Journal of Clinical Oncologn. 2002;20:1578–1583
  62. McNagny SE. Clinical review: prescribing hormone replacement therapy for menopausal symptoms. Annals of Internal Medicine. 1999;131:605–616
  63. Nelson HD, Humphrey LL, Nygren MA, et al.  Postmenopausal hormone replacement therapy: scientific review. Journal of the American Medical Association. 2002;288:872–881
  64. DiSaia PJ, Brewster WR, Ziogas A, Anton-Culver H. Breast cancer survival and hormone replacement therapy: a cohort analysis. American Journal of Clinical Oncology. 2000;23:541–545
  65. Hickman TN, Namnoum AB, Hinton EL, et al.  Timing of estrogen replacement therapy following hysterectomy with oophorectomy for endometriosis. Obstetrics and Gynecology. 1998;91:673–677
  66. Ang WC, Farrell E, Vollenhoven B. Effect of hormone replacement therapies and selective estrogen receptor modulators in postmenopausal women with uterine leiomyomas: a literature review. Climacteric. 2001;4:284–292
  67. Effects of menopause and estrogen replacement therapy or hormone replacement therapy in women with diabetes mellitus: consensus opinion of the North American Menopause Society. Menopause. 2000;7:87–95

PII: S1521-690X(02)00087-8

doi: 10.1016/S1521-690X(02)00087-8

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 17, Issue 1 , Pages 1-16 , March 2003

Article Tools